It is time to register!
This one-mile walk down Greenwich Avenue is about honoring and remembering our loved ones, friends and colleagues who have faced breast cancer head on, and about coming together as friends, family, and neighbors to show our support and raise money to help BCA do its part to eradicate this disease. What better way to spend a Sunday morning? This event is RAIN OR SHINE and walk-in registrations are welcome, though pre-registration is preferred.
WHEN: Sunday, April 27, 2014
10:30am Check-in, Health Fair Opens, Music & Complimentary Breakfast
11:00am Welcome & Walk
12:00pm Health Fair & Refreshments Continue
WHERE: Richards, 359 Greenwich Avenue, Greenwich, CT
WHAT: One Mile Walk starting up Mason Street, returning via Greenwich Avenue
WHO: Co-Chairs: Caroline Brecker, Nicole Ewing, Julie Genovese ~ Grand Marshall: Trisha Goddard of NBC Universal’s syndicated talk show “Trisha”
PLATINUM SPONSOR: Omnicom
Early supporters include: Baywater Properties/The Genovese Family, Becker Salon, Greenwich Hospital, Hat Attack/Buji Baja, Equinox, The Mifflin Family, PepsiCo, Rand Insurance, Richards, and Z Hospitality Group…and many more to come!
COST: $20 per adult, $10 per student, kids under 7 (and dogs in pink!) are free
HOW: To register as an individual, a family, or a team, or if you cannot attend but want to make a donation, click here
SPONSORSHIPS: To become an event sponsor, click on Corporate Sponsorship Opportunities 2014 for details
Each year our Juniors hit the runway in the latest Spring fashions at Richards to do their own fundraising for the BCA and this year is no different!
On Sunday, April 6 at 11:30am, students from 7 different high schools in Connecticut and Westchester will be modeling and putting together a great silent auction to help expand the work of Breast Cancer Alliance.
To join us for this event, or to make a donation to support our teens, go to: http://weblink.donorperfect.com/juniorfashionshow2014Read More
Click here to read the latest issue of our newsletter, Outlook, online! If you prefer to receive a hard copy, please contact the office to be sure you are on our mailing list at email@example.com.Read More
Each year, in accordance with our commitment to due diligence, we visit each of the institutions to whom we provide a grant allocation.
The dates for this year’s visits on the calendar thus far are listed below. If you would like to attend one of these visits, or receive more information about timing and content, please contact Crystal Stoute, Executive Assistant, at firstname.lastname@example.org.
New York University, Dr. Agnel Sfeir: Dr. Sfeir’s project is examining whether there may be additional bases for inherited breast cancers in DNA repair pathways, and why BRCA cancers may be resistant to PARP inhibitors
May 9: Griffin Hospital and Middlesex Hospital
Massachusetts Institute of Technology
Michael B. Yaffe, Paula T. Hammond: Dr. Yaffe and Dr. Hammond have designed a drug delivery system for time-staggered release of a combination of chemotherapeutic agents that is aimed at rendering triple negative breast cancers more sensitive to chemotherapy.
Richard O. Hynes: Dr. Hynes is studying extracellular matrix proteins (ECMs) associated with tumors. An aim of the project is to develop a panel of antibodies that are specific to individual ECMs, with an eye to identifying those ECMs that may be useful in diagnosis and prognosis, as well as potential use of antibodies in tumor imaging and targeting.
The Brigham and Women’s Hospital, Sandra S. McAllister: Dr. McAllister’s research is examining the behavior of individual disseminated breast tumor cell lines to determine which characteristically become malignant and which remain indolent; this may lead to the ability to diagnose which patients are most susceptible to relapse, and possible new therapeutic strategies.
Harvard College, Joan S. Brugge: Dr. Brugge has developed isolated clonal cell lines from patients’ triple negative breast tumors, and will study each cell line’s response to standard chemotherapy regimens, to determine which are sensitive to chemotherapy, and which are prominent in relapsed tumors.
June 5: Greenwich Hospital
June 10: Rutgers Cancer Institute of NJ, fellowship report
June 17: Beth Israel Medical Center/St. Luke’s-Roosevelt, fellowship report
June 25: Norwalk Hospital/Whittingham Cancer Center
July 9: Hospital of Central Connecticut and Hartford Hospital
July 16: Open Door
July 22: Yale-New Haven and St. Raphael’s Hospital
September 9: Gilda’s Club
September 16: Norma F. Pfriem Breast Care Center, St. Vincent’s Hospital and The Witness Project
Thomas Jefferson University, Hallgeir Rui: Dr. Rui has developed a mouse model, expressing human prolactin hormone, that is duplicative of the human system with breast cancer. This model is being used to test the efficacy of prolactin suppression alone or in combination with anti-estrogens on lung metastases after removal of a primary tumor.
Weill Medical College of Cornell University, Lewis (Lew) S. Cantley (with Gerburg M. Wulf on skype): Dr. Cantley and Dr. Wulf are using mouse models to determine which combinations of PI3K (a known cancer promoter) inhibitors and other chemotherapeutic agents have a beneficial effect on cancers that do not respond to estrogen receptor blockers or Her-2 blocking agents.
October 14: Stamford Hospital
Dana-Farber Cancer Institute
Constantine S. Mitsiades: Dr. Mitsiades has previously observed that “accessory” non-metastatic cells aid metastatic cells in their resistance to chemotherapy. The present study is examining the mechanisms by which these accessory cells may work in aiding estrogen-receptor mutated tumor cells in becoming resistant to anti-estrogen therapies, in the context of bone metastases, the most common, but infrequently studied, of breast cancer metastatic sites.
Kornelia (Nelly) Polyak: Based on prior observations of metabolic differences between tumor cells and normal cells, Dr. Polyak’s study is looking at the role that metabolic changes induced by stromal (normal) cells play in the development of tumor cells’ therapeutic resistance, with an aim to identify possible metabolic pathways as therapeutic targets.Read More